Inclusion Criteria:

          -  The patient must have a diagnosis of one of the following (one must be yes):

               -  Bone marrow failure disorders:

                    -  Acquired bone marrow failure disorders include aplastic anemia, paroxysmal
                       nocturnal hemoglobinuria (PNH):

                         -  SAA must have failed at least one cycle of standard immunosuppressive
                            therapy with calcineurin inhibitor plus anti-thymocyte globulin (ATG)
                            if a fully-matched donor is not available

                         -  PNH must have failed treatment or not tolerated treatment with
                            eculizumab or progressed during or after treatment with eculizumab)

                    -  Hereditary bone marrow failure disorders include Diamond-Blackfan anemia,
                       Shwachman-Diamond syndrome, Kostmann syndrome, and congenital
                       amegakaryocytic thrombocytopenia

               -  Other non-malignant hematologic or immunologic disorders that require
                  transplantation:

                    -  Quantitative or qualitative congenital platelet disorders (including but not
                       limited to congenital amegakaryocytopenia, absent-radii syndrome,
                       Glanzmann's thrombasthenia)

                    -  Quantitative or qualitative congenital neutrophil disorders (including but
                       not limited to chronic granulomatous disease, congenital neutropenia)

                    -  Congenital primary immunodeficiencies (including but not limited to severe
                       combined immunodeficiency syndrome, Wiskott-Aldrich syndrome, CD40 ligand
                       deficiency, T-cell deficiencies)

                    -  Hemoglobinopathies (including sickle cell disease and thalassemia

               -  Acute leukemias:

                    -  Acute myeloid leukemia (AML) - antecedent myelodysplastic syndrome,
                       secondary AML, high risk cytogenetic abnormalities or normal cytogenetics
                       with high-risk molecular mutations (including but not limiting to Flt3-ITD
                       mutation)

                    -  Acute lymphoblastic leukemia (ALL) B cell or T cell

               -  Chronic myelocytic leukemia (CML):

                    -  Chronic phase (intolerant or unresponsive to imatinib and/or tyrosine kinase
                       inhibitors)

                    -  Second chronic phase or accelerated phase who are ineligible for
                       conventional myeloablative transplantation

               -  Myeloproliferative and myelodysplasia syndromes:

                    -  Myelofibrosis (with/without splenectomy) with intermediate to high risk
                       features

                    -  Advanced polycythemia vera not responding to therapy

                    -  Myelodysplastic syndrome (MDS) with an International Prognostic Scoring
                       System (IPSS) score of intermediate or higher

                    -  Secondary MDS with any IPSS score

                    -  Chronic myelomonocytic leukemia (CMML)

               -  Lymphoproliferative disease:

                    -  Chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin lymphoma (NHL)
                       (recurrent or persistent) cytotoxic therapy refractory or with less than 6
                       months duration of complete response (CR) between courses of conventional
                       therapy

                    -  Multiple myeloma (MM) progressive disease after auto bone marrow
                       transplantation (BMT), tandem allo after prior auto

                    -  Waldenstrom's macroglobulinemia (failed one standard regimen)

                    -  T or B cell lymphoma with poor risk features

                    -  Hodgkin disease:

                         -  Received and failed frontline therapy

                         -  Failed or not eligible for autologous transplantation

          -  Suitable related haploidentical donor identified:

               -  Must be matched at least at 5 of 10 HLA antigens (A, B, C,DRB1, DQ)

               -  Must not be matched at more than 7 of 10 HLA antigens

               -  Recipient should not have HLA antibodies to potential donor; if the recipient
                  does have HLA antibodies to the potential donor, an alternative donor is
                  preferred; however, if there are no suitable alternative donors, the donor to
                  whom the patient has HLA antibodies can be utilized as long as the antibody titer
                  is less than 2000 median fluorescence intensity (MFI); if the titer is > or = to
                  2000 MFI, the recipient must undergo successful antibody desensitization prior to
                  enrollment on this study; any patients who have demonstrated donor specific
                  antibodies will not be evaluated for the end points measured in this study but
                  will be followed for treatment related toxicities

               -  Haploidentical donors that are ABO compatible with the recipient are preferred.
                  Minor ABO incompatibility is preferred to major ABO incompatibility. Major ABO
                  incompatibility between recipient and donor is the least preferred but still
                  acceptable for this study.

               -  It is preferred that the haploidentical donor must be available to donate on day
                  -1 and day 0, so that fresh product can be processed by the Stem Cell lab and
                  administered to the patient on day 0.. While less preferable, cryopreserved
                  product may be utilized with this product.

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) > 40% predicted, corrected
             for hemoglobin and/or alveolar ventilation

          -  Left ventricular ejection fraction > 40%

          -  Bilirubin, liver alkaline phosphatase, serum glutamic-oxaloacetic transaminase (SGOT)
             or serum glutamate pyruvate transaminase (SGPT) =< 3 x upper limit of normal

          -  Calculated creatinine clearance > 40 cc/min by the modified Cockcroft-Gault formula
             for adults or the Schwartz formula for pediatrics

          -  Have a Karnofsky (adult) or Lansky (for =< 16 years) performance status >= 60%

          -  Patient must be able to pass radiation evaluation (i.e.: able to receive 200 cGy)

          -  Patients who have failed a prior autologous transplant are eligible; however, at least
             90 days must have elapsed between the start of this reduced intensity conditioning
             regimen and the last transplant if patient had a prior autologous BMT

          -  Participants of child-bearing potential must agree to use adequate contraceptive
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study
             entry; should a woman become pregnant or suspect she is pregnant while she or her
             partner is participating in this study, she should inform her treating physician
             immediately

          -  Participant must understand the investigational nature of this study and sign an
             independent ethics committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure

          -  Patient in CR or has a bone marrow failure disorder or non-malignant hematologic or
             immune disorder : does NOT have a sibling donor or 12/12 HLA matched unrelated donor
             available OR treating clinician considers haploidentical transplant referable (despite
             sibling donor availability or 12/12 HLA matched donor availability) due to patient's
             clinical status.

          -  Exclusion Criteria:

          -  Participants who have had chemotherapy, radiation treatment and/or surgery 2 weeks
             prior to entering the study or, as per discretion of the treating physician, those who
             have not recovered sufficiently from adverse events due to agents administered more
             than 2 weeks earlier

          -  Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)

          -  Child-Pugh class B and C liver failure

          -  Concomitant active malignancy that would be expected to require chemotherapy within 3
             years of transplant (other than non-melanoma skin cancer)

          -  Patients who have received maximally allowed doses (given in 2 Gy fractionations, or
             equivalent) of previous radiation therapy to various organs; patients who previously
             have received a higher than allowed dose of radiation to a small lung, liver and brain
             volume, will be evaluated by the radiation oncologist to determine if the patient is
             eligible for study

          -  Uncontrolled diabetes mellitus, cardiovascular disease, active serious infection or
             other condition which, in the opinion of treating physician, would make this protocol
             unreasonably hazardous for the patient

          -  Known human immunodeficiency virus (HIV) positive

          -  Pregnant or nursing female participants

          -  Patients who in the opinion of the treating physician are unlikely to comply with the
             restrictions of allogeneic stem cell transplantation based on formal psychosocial
             screening

          -  Patients with donor specific HLA antibodies with a titer greater than 2000 MFI
             (whether or not they have undergone a desensitization protocol)

          -  Patients who have undergone a prior allogeneic hematopoietic or (other organ)
             transplant

          -  Treating physician considers the potential HLA haploidentical donor to be ineligible
             to receive G-CSF, and/or concern on the part of the treating physician for risk of
             harm to the potential donor with administration of G-CSF, and/or refusal by the
             potential donor (or donor's guardian) to receive G-CSF

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug

          -  Received an investigational agent within 30 days prior to enrollment